Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8518248 | 1.00 | TNKS2 (0.40) | TNKS2PARP2TOP2ASMN1; SMN2TSHR | |
| SCHEMBL30146470 | 0.79 | MAPT (0.38) | MAPT | |
| SCHEMBL30013514 | 0.77 | KDM4E (0.35) | HSD17B10LMNAMAOAKDM4EMAPT | |
| SCHEMBL30961068 | 0.77 | KMO (0.36) | KDM4EMAPT | |
| SCHEMBL30578403 | 0.75 | TSHR (0.39) | TNKS2PARP2TOP2ASMN1; SMN2TSHR | |
| SCHEMBL1598267 | 0.73 | SMN1; SMN2 (0.50) | TNKS2PARP2TOP2ASMN1; SMN2TSHR | |
| SCHEMBL30013801 | 0.73 | SMN1; SMN2 (0.50) | TNKS2PARP2TOP2ASMN1; SMN2TSHR | |
| SCHEMBL5909487 | 0.72 | BACE1 (0.40) | HSD17B10HPGDKDM4EMAPT | |
| SCHEMBL31605956 | 0.72 | BACE1 (0.40) | HSD17B10HPGDKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL11775175 | 0.72 | SMN1; SMN2 (0.49) | TNKS2PARP2TOP2ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| EP-4359415-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | TNKS2 497/4885PARP2 1465/4885TOP2A 3292/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | TNKS2 497/4885PARP2 1465/4885TOP2A 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.